Jazz Pharmaceuticals (JAZZ) Current Assets (2010 - 2026)

Jazz Pharmaceuticals' Current Assets history runs 17 years deep, the most recent figure standing at $4.6 billion for Q1 2026.

• In Q1 2026, Current Assets rose 11.03% year-over-year to $4.6 billion; the TTM figure through Mar 2026 stood at $4.6 billion (up 11.03% YoY), while the FY2025 annual figure was $4.2 billion, down 10.0% from the prior year.
• Current Assets for Q1 2026 stood at $4.6 billion, up from $4.2 billion in the prior quarter.
• The five-year high for Current Assets was $4.6 billion in Q4 2024, with the low at $2.5 billion in Q1 2022.
• The 5-year median for Current Assets is $3.4 billion (2023), against an average of $3.5 billion.
• The sharpest annual moves came in 2022 and 2024: Current Assets declined 21.03% in 2022, then jumped 35.27% in 2024.
• Jazz Pharmaceuticals' Current Assets stood at $2.6 billion in 2022, then surged by 31.82% to $3.4 billion in 2023, then surged by 34.74% to $4.6 billion in 2024, then decreased by 10.0% to $4.2 billion in 2025, then grew by 10.01% to $4.6 billion in 2026.
• Business Quant data shows JAZZ's Current Assets at $4.6 billion in Q1 2026, $4.2 billion in Q4 2025, and $3.8 billion in Q3 2025.